EMA panel backs Ascendis Pharma's weekly growth drug YUVIWEL for achondroplasia in Europe

What's the news? The European Medicines Agency's human medicines committee (CHMP) has recommended approval of Ascendis Pharma's once-weekly medicine YUVIWEL (navepegritide) for achondroplasia in children two years and older whose growth plates are still open. The positive opinion was adopted on 15 October 2026; the European Commission is expected to take a final decision in the fourth quarter of 2026, with a first EU launch planned in Germany in early 2027.

Why it matters: Achondroplasia is the most common form of dwarfism, caused by overactive signalling that restricts bone growth. YUVIWEL works by supplying C-type natriuretic peptide (CNP), a protein that counteracts this overactive growth-hormone-type signalling, delivering it continuously over a full week from a single injection. It is the only approved therapy that provides continuous systemic exposure to active CNP across the weekly dosing interval. The US Food and Drug Administration already approved YUVIWEL under an accelerated approval in February 2026, and the CHMP opinion was based on three randomised, placebo-controlled trials plus up to three years of follow-up data.

Read more: EMA, 16 October 2026 · BioSpace, 16 October 2026